FDA Approval of Palbociclib in Combination with Fulvestrant for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer

On February 19, 2016, the FDA approved palbociclib (Ibrance, Pfizer) for use in combination with fulvestrant (Faslodex, AstraZeneca) for the treatment of women with hormone receptor (HR)-positive, HER2-negative advanced or metastatic breast cancer (MBC) with disease progression following endocrine t...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research 2016-10, Vol.22 (20), p.4968-4972
Hauptverfasser:	Walker, Amanda J, Wedam, Suparna, Amiri-Kordestani, Laleh, Bloomquist, Erik, Tang, Shengui, Sridhara, Rajeshwari, Chen, Wei, Palmby, Todd R, Fourie Zirkelbach, Jeanne, Fu, Wentao, Liu, Qi, Tilley, Amy, Kim, Geoffrey, Kluetz, Paul G, McKee, Amy E, Pazdur, Richard
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged Aged, 80 and over Antineoplastic Agents, Hormonal - adverse effects Antineoplastic Agents, Hormonal - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use Breast Neoplasms - drug therapy Breast Neoplasms - pathology Disease-Free Survival Drug Approval Estradiol - adverse effects Estradiol - analogs & derivatives Estradiol - therapeutic use Female Humans Middle Aged Piperazines - adverse effects Piperazines - therapeutic use Protein Kinase Inhibitors - therapeutic use Pyridines - adverse effects Pyridines - therapeutic use Receptor, ErbB-2 - metabolism Receptors, Estrogen - metabolism Receptors, Progesterone - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!